Secular Trends And Cell Therapies Will Expand Markets Despite Risks

Published
17 Apr 25
Updated
15 Aug 25
AnalystHighTarget's Fair Value
US$17.87
28.6% undervalued intrinsic discount
15 Aug
US$12.76
Loading
1Y
-49.8%
7D
5.5%

Author's Valuation

US$17.9

28.6% undervalued intrinsic discount

AnalystHighTarget Fair Value

Shared on07 May 25
Fair value Decreased 26%

Shared on30 Apr 25
Fair value Decreased 15%

AnalystHighTarget has decreased future PE multiple from 32.7x to 28.8x.

Shared on23 Apr 25
Fair value Increased 16%

AnalystHighTarget made no meaningful changes to valuation assumptions.